Key result
A literature review on pediatric hyperlipidemia highlights its growing prevalence as a cardiovascular risk factor and the lack of clear guidelines for cholesterol screening and therapy initiation.
Why the study?
Hyperlipidemia is rising in children and contributes to cardiovascular disease and high mortality, yet clear pediatric guidelines for cholesterol screening and therapy initiation timing are lacking.
This review highlights the growing global burden of pediatric hyperlipidemia and the urgent need for clear clinical guidelines on screening and treatment initiation in children.
Urges clinical caution in pediatric hyperlipidemia absent guidelines; leaves open standardized screening and treatment thresholds for prospective trials.
The article presents literature review findings on the prevalence, diagnosis, and treatment of hyperlipidemia, including familial hypercholesterolemia in children. It is noted that the number of patients with hyperlipidemia continues to grow throughout the world. As before, hyperlipidemias are considered risk factors for the development of cardiovascular diseases and the cause of high mortality in different countries of the world. Attention is drawn to the possibility of atherosclerotic lesions of the heart vessels in young people and adolescents. Diseases in children (diabetes mellitus, obesity, hypothyroidism, renal pathology, etc.) have been noted, which necessitate diagnosing hyperlipidemia. There are no clear guidelines for pediatricians regarding cholesterol screening and timing of therapy initiation.
No takes yet. Share an insight, caveat, or question.
Nikitina et al. (2023) conducted a review in Hyperlipidemia in children. Hyperlipidemia was evaluated. A literature review on pediatric hyperlipidemia highlights its growing prevalence as a cardiovascular risk factor and the lack of clear guidelines for cholesterol screening and therapy initiation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: